Clinical Trials Directory

Trials / Completed

CompletedNCT02857634

Confocal Microscopy Dual Band in the Management of Bladder Cancer

Study of the Contribution of Confocal Microscopy Dual Band in the Management of Bladder Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
3 (actual)
Sponsor
Lille Catholic University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Bladder cancer is one of the most common cancer worldwide and the second most frequent urological cancer. The photodynamic diagnosis technique (PDD) currently used (Hexvix®) has improved tumor detection but with a high false positive rate. Indeed, the main limitation of the PDD is its lack of specificity, ranging from 35 to 66%. The association of this technique with new technologies such as the Cellvizio Dual Band featuring simultaneous dual wavelength illumination and detection, could improve the identification of tumoral lesions. The objective of this study is to demonstrate the efficacy of Cellvizio dual band technique for the diagnosis of tumors bladders.

Conditions

Interventions

TypeNameDescription
DEVICECellvizio dual bandUsing fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.

Timeline

Start date
2016-07-01
Primary completion
2016-09-01
Completion
2016-09-01
First posted
2016-08-05
Last updated
2018-10-31

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02857634. Inclusion in this directory is not an endorsement.